NXY-059
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Aug 1, 2004 → Jan 1, 2006
NCT ID
NCT00075959About NXY-059
NXY-059 is a phase 2 stage product being developed by AstraZeneca for Intracerebral Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00075959. Target conditions include Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00075959 | Phase 2 | Completed |
| NCT00119626 | Phase 3 | Completed |
| NCT00061022 | Phase 3 | Completed |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |
| Albumin + Placebo | Baxter | Phase 2 | 49 |